- Investing Ideas
- Swiss Pharmaceuticals & Biotech Large Cap High Growth Potential
Swiss Pharmaceuticals & Biotech Large Cap High Growth Potential
Results
4
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
4 companies
Galderma Group
Market Cap: CHF 37.3b
Operates as a dermatology company worldwide.
GALD
CHF 161.50
7D
-3.0%
1Y
39.3%
Sandoz Group
Market Cap: CHF 27.5b
Develops, manufactures, and markets generic and biosimilars worldwide.
SDZ
CHF 64.40
7D
-1.8%
1Y
46.3%
Novartis
Market Cap: CHF 212.1b
Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
NOVN
CHF 117.98
7D
0.1%
1Y
21.5%
Lonza Group
Market Cap: CHF 34.3b
Operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
LONN
CHF 485.60
7D
-3.0%
1Y
-15.3%